DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Sunday. The firm issued a hold rating on the stock.

Several other brokerages also recently weighed in on DBVT. HC Wainwright restated a buy rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities increased their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the company a market outperform rating in a research note on Wednesday, July 31st.

DBV Technologies Stock Up 1.2 %

DBVT opened at $0.93 on Friday. DBV Technologies has a 52-week low of $0.50 and a 52-week high of $3.70. The company has a 50 day moving average of $0.90 and a two-hundred day moving average of $1.24. The company has a market cap of $89.57 million, a P/E ratio of -1.11 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter last year, the company posted ($0.26) earnings per share. Research analysts anticipate that DBV Technologies will post -1.22 earnings per share for the current year.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.